Metraipolis › archive › dc_1cb84f2f01df
Subcutaneous versus intravenous trastuzumab for HER2-positive breast cancer: a global systematic review and meta-analysis with a cost-minimization analysis… — Europe PMC PMID:41573718
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41573718
- DOI
- 10.3389/fphar.2025.1730175
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T00:38:32.777Z
- SHA-256 of the archived text
918b76d8177812be759ea70814ee42b2d11cc732bd601c7875f0333667e0d316- Stable URL of this page
https://metraipolis.com/documento/dc_1cb84f2f01df
How to cite
Subcutaneous versus intravenous trastuzumab for HER2-positive breast cancer: a global systematic review and meta-analysis with a cost-minimization analysis… — Europe PMC PMID:41573718 — Europe PMC (en), https://europepmc.org/article/MED/41573718 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1cb84f2f01df (Metraipolis archive dc_1cb84f2f01df, sha256 918b76d8177812be759ea70814ee42b2d11cc732bd601c7875f0333667e0d316)
BibTeX
@misc{dc1cb84f2f01df,
title = {Subcutaneous versus intravenous trastuzumab for HER2-positive breast cancer: a global systematic review and meta-analysis with a cost-minimization analysis… — Europe PMC PMID:41573718},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41573718},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1cb84f2f01df; sha256 918b76d8177812be759ea70814ee42b2d11cc732bd601c7875f0333667e0d316},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41573718. Agents can read the archived copy with the MCP tool read_document.